Re: Sixth Annual RNAi Roundtable Series - TTRsc02 on Monday next week
Near term it will not be good for Alnylam if most patients switch to Vutrisiran. Alnylam doesn’t have to share its revenue on Onpattro with Genzyme but it has to give, I believe, up to 30% of its revenue on Vutrisiran to Genzyme. That is not good unless it captures more market share with Vutrisiran. I think company will try to keep patients on Onpattro as much as it can.